CXCL10 and lung carcinoma: To further investigate the hypothesis in clinical, we compared the difference between healthy volunteers and lung cancer patients for recognizing RT- or IFNγ-treated tumors, PD-1, a gene binding to PD-L1, CXCR3, a gene binding to CXCL10 for activating LFA-1, and LFA-1 levels were measured using flow cytometry.